Background. Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HBV) DNA levels are major factors affecting the prognosis of adult HBV carriers; however, the impact of viral load on long-term outcomes after spontaneous HBeAg seroconversion remains unclear.
, 2 3 10 4 22 3 10 5 , and $2 3 10 5 IU/mL. In addition, serum HBV-DNA levels were independently associated with HBeAg-negative hepatitis flare, which confirmed their impact on the immune active hepatitis after HBeAg seroconversion.
Conclusions. HBeAg seroconversion may not always confer favorable outcomes. Serum HBV-DNA levels $2000 IU/mL at 1 year post HBeAg seroconversion correlate with increased risk of HBeAg-negative hepatitis and hepatitis flare.
Hepatitis B virus (HBV) infection is a global health problem, with 1 million people dying from related complications per year [1] . Patients with chronic HBV infection are at an increased risk of developing liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC) [1, 2] . It is estimated that 25%-40% of HBV carriers who acquire the virus early in life will eventually develop these serious complications [2] .
According to the natural history of HBV infection, spontaneous hepatitis B e antigen (HBeAg) seroconversion usually confers a favorable outcome because of a restoration of HBV-specific host immunity, a decline in viral replication, and a remission of hepatic necroinflammation [2, 3] . However, approximately 20%-30% of HBeAg seroconverters enter an ''HBeAg-negative hepatitis phase'' during the followup, which is a major risk factor for subsequent cirrhosis and HCC development [4] [5] [6] [7] . Therefore, early identification of patients at risk of developing HBeAgnegative hepatitis is mandatory because prompt antiviral treatment may reduce or prevent their disease progression.
Several longitudinal studies on HBeAg seroconverters showed that male sex, HBV genotype C infection, and older age at HBeAg seroconversion are all associated with the emergence of HBeAgnegative hepatitis [5, [7] [8] [9] [10] [11] . According to a prospective cohort study from Taiwan, higher serum HBV-DNA levels in adult HBV carriers indicate an increased risk of cirrhosis and HCC over time [12, 13] . However, little is known about the impact of serum HBV-DNA levels on the emergence of HBeAg-negative hepatitis, a precursor of cirrhosis and HCC, in spontaneous HBeAg seroconverters.
To address this important issue, a hospital-based cohort study was conducted. It enrolled patients with chronic HBV infection who experienced spontaneous HBeAg seroconversion and received long-term follow-up [14] . We explored the association between the HBV-DNA levels post HBeAg seroconversion and HBV-related complications, including HBeAg-negative hepatitis, hepatitis flare, cirrhosis, and HCC, in this cohort. Through a comprehensive analysis of HBeAg-negative phase, we aimed to clarify the impact of HBV-DNA levels post HBeAg seroconversion on disease progression. Figure 1 shows the flow of patients included into the Study of E Antigen seRoClearance of Hepatitis B patients (SEARCH-B). From 1985 to 2004, a total of 1278 HBeAg-positive chronic hepatitis B patients .16 years of age who received regular follow-up for .3 years at the National Taiwan University Hospital were consecutively enrolled. All of them had been HBsAg-positive for .6 months, and none had evidence of concomitant hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus infection. With a mean follow-up period of 5.5 6 4.8 years, 490 patients developed spontaneous HBeAg seroconversion. We excluded patients who developed HBeAg seroreversion (n 5 19) and those who met the designated end points before the end of the first year post HBeAg seroconversion (for HBeAg-negative hepatitis, n 5 26; for cirrhosis, n 5 33; for HCC, n 5 3). Of the remaining 409 patients with spontaneous HBeAg seroconversion, 7 did not receive regular follow-up and 12 did not have adequate serum samples for molecular analysis and were thus excluded from the study. A total of 390 spontaneous HBeAg seroconverters were included in the final analysis.
MATERIALS AND METHODS

Patient Cohort
Every enrolled patient signed the informed consent approved by the ethical committee of the National Taiwan University Hospital for both blood sampling and testing.
Data Collection
During the follow-up period, patients were tested for serological markers (HBsAg, HBeAg, anti-HBe, anti-HCV, and anti-HDV), liver function tests, and a-fetoprotein levels at baseline.
Liver function tests and a-fetoprotein levels were tested every 6 months or more frequently if clinically indicated. HBeAg and anti-HBe were assayed at least every 6 months within the first year post HBeAg seroconversion and when hepatitis occurred thereafter. Serum samples collected were stored at 220°C until tested. Abdominal ultrasound examination using a high-resolution, real-time scanner was performed at least every 6 months after enrollment to detect cirrhosis or HCC.
Pilot Study to Determine the Appropriate Timing of HBV-DNA Quantification According to our previous viral kinetic study on spontaneous HBeAg seroconverters, serum HBV-DNA levels were still high at the time of HBeAg seroconversion (median .2 3 10 4 IU/mL) and tended to stabilize at 1 year post HBeAg seroconversion [15] . To decide the most appropriate time point for HBV-DNA quantification, we conducted a pilot study, which enrolled 42 HBeAg seroconverters with comprehensive viral kinetic data. Serum HBV-DNA levels were determined at different time points to correlate with the risk of HBeAg-negative hepatitis.
Criteria to Diagnose End Points
HBeAg seroconversion was defined as persistent HBeAg negativity and anti-HBe positivity for at least 1 year. HBeAg-negative hepatitis was defined as alanine aminotransferase (ALT) elevation more than twice the upper limit of normal (ULN) with a concomitant serum HBV-DNA level $2000 IU/mL [16] [17] [18] . HBeAgnegative hepatitis flare was defined as ALT elevation .5 times the ULN with a concomitant serum HBV-DNA level $2000 IU/mL [16] . The ULN for serum ALT level is 40 U/L. Apart from the aforementioned criteria, exclusion of drug or alcohol use and the absence of serological evidence suggestive of other viral hepatitis infection or autoimmune liver disease was essential to ensure the correct diagnosis. Diagnosis of liver cirrhosis was determined either by histological findings or by ultrasonographic findings supplemented with clinical features such as thrombocytopenia, esophageal varices, or ascites as described previously [4, 7, 19] . For the diagnosis of cirrhosis to be made via abdominal ultrasound, it had to be consistently diagnosed on at least 2 occasions 6 months apart [13] . Liver biopsy to detect cirrhosis was not regularly performed in this study due to its potential risk of hazard complication. Liver biopsy was performed when the etiology of hepatitis could not be ascertained (HBV-DNA quantification was not widely used before the early 2000s) and patients were convinced to receive it or when patients started to receive antiviral therapy, which was reimbursed by the Bureau of National Health Insurance in Taiwan since 2004 [20] . HCC was diagnosed either by histology/cytology or by typical imaging findings (computed tomography or magnetic resonance) plus a serum level of a-fetoprotein .200 ng/mL, according to the current guideline [21] . 
Serological Assays
Serum HBsAg, HBeAg, anti-HBe, anti-HCV, and anti-HDV were tested using commercially available kits (Abbott Laboratories).
Extraction of Viral DNA Viral DNA in the serum was extracted using commercial kits (QIAamp DNA Blood and Tissue Mini Kit; Qiagen). The extracted DNA was used for HBV-DNA quantification and HBV genotyping.
Quantification of Serum HBV-DNA Level and HBV Genotyping
Serum HBV-DNA levels and genotype were determined using real-time polymerase chain reaction (PCR)-based single-tube assay as described previously [22] . In short, this method consists of 2 consecutive steps. The first step uses real-time PCR to quantify HBV-DNA, and the second step uses melting curve analysis to genotype HBV. The detection limit of HBV-DNA level is 20 IU/mL (100 copies/mL). Because HBV genotype is presumed to be constant throughout infection, available serum samples from the HBeAg-positive stage were used to genotype HBV in patients with undetectable viral load at the indicated time. In addition, serum HBV DNA levels at 1 year post HBeAg seroconversion in the cohort study were determined retrospectively using the stored sera.
Statistical Analysis
Means and standard deviations were calculated for continuous variables. Percentage was used for categorical variables. Follow-up started from 1 year after HBeAg seroconversion because the last test of serum viral load was at the end of the first year after HBeAg seroconversion. The person-years were censored on the date of diagnosis of the aforementioned end points, the date of initiation of antiviral therapy, the last date of follow-up, or 30 June 2008, whichever came first. For patients with multiple episodes of HBeAg-negative hepatitis or hepatitis flare, each end point was only counted once in each patient. The cumulative incidences of designated end points by different variables were derived using the Kaplan-Meier method, and the statistical difference was derived from the log-rank test.
The Cox proportional hazards model was used to calculate the crude hazard ratio (HR) of each end point associated with different risk factors. Serum HBV-DNA levels were categorized into 2 groups, ,2000 IU/mL and .2000 IU/mL, in the pilot study due to the small patient number. For the cohort study, serum HBV-DNA levels were categorized into ,200 IU/mL, 200-1999 IU/mL, 2000-19 999 IU/mL, 20 000-199 999 IU/mL, and .200 000 IU/mL. The dose-response relationship between serum HBV-DNA levels and the risk of all 4 end points were examined for statistical significance with a test for trend. Multivariable-adjusted HRs and 95% confidence intervals (CIs) were derived for each factor.
To determine the predictive value of HBV-DNA levels, we restricted the study population to patients who were followed up for at least 3 years and computed the 3-year risk of HBeAgnegative hepatitis under different cutoffs for HBV-DNA levels. The same approach was also used to evaluate the 6-year risk of HBeAg-negative hepatitis. Receiver-operating characteristic (ROC) curve analysis was used to calculate the area under the ROC curve (AUROC), which was used to evaluate the predictive performance of HBV-DNA levels for 3-year and 6-year HBeAgnegative hepatitis.
The relationships of HBeAg-negative hepatitis and hepatitis flare with the development of cirrhosis and HCC were analyzed. Both cirrhosis and HCC development were designed as binary outcomes. The odds ratio (OR) and 95% CI of each factor were derived using logistic regression analysis.
The statistical significance of all tests was defined as P , .05 by 2-tailed tests. All analyses were performed using Stata statistical software (version 9.2; StataCorp).
RESULTS
Pilot Study
We first investigated the relationship between cumulative incidence of HBeAg-negative hepatitis and serum HBV-DNA levels in 42 spontaneous HBeAg seroconverters (Figure 2) . A significant association existed only when the serum HBV-DNA level was determined at 1 year post HBeAg seroconversion (P 5 .001) but not at the time of HBeAg seroconversion (P 5 .337) or at 6 months post HBeAg seroconversion (P 5 .278). Therefore, serum HBV-DNA levels at 1 year post HBeAg seroconversion were chosen to correlate with long-term outcomes in the cohort study. Table 1 shows the demographic data of 390 spontaneous HBeAg seroconverters. At 1 year post HBeAg seroconversion, 120 patients (30.8%) had HBV-DNA levels ,20 IU/mL, and 19 patients (4.8%) had HBV-DNA levels of 20-199 IU/mL. These two groups were combined into a group with HBV-DNA levels ,200 IU/mL due to the small patient number in the latter group. During the follow-up, 18 (4.6%) patients received antiviral therapy as a result of developing HBeAg-negative hepatitis (2 with pegylated interferon alfa-2a 7 with lamivudine, 1 with adefovir dipivoxil, and 8 with entecavir).
Baseline Characteristics of 390 Spontaneous HBeAg Seroconverters
Cumulative Incidence of HBeAg-Negative Hepatitis, HBeAg-Negative Hepatitis Flare, Cirrhosis, and HCC There were 2666.6, 2998.6, 3172.7, and 3322.9 person-years of follow-up for the end points of HBeAg-negative hepatitis, HBeAg-negative hepatitis flare, cirrhosis, and HCC, respectively. The different numbers of person-years were due to different definitions of every end point. The average follow-up periods were 6.8 years, 7.7 years, 8.1 years, and 8.5 years, respectively.
Throughout the follow-up, 116 patients developed HBeAgnegative hepatitis, 56 developed HBeAg-negative hepatitis flare, 28 developed cirrhosis, and 8 developed HCC. The average annual incidence rates were 4.4%, 1.9%, 0.9%, and 0.2%, respectively. The 5-year cumulative incidences were 25.2%, 12.3%, 5.5%, and 0.9%, respectively. Of the 28 patients who developed cirrhosis, none of them showed evidence of liver cirrhosis before the first year post HBeAg seroconversion; 22 (78.6%) were diagnosed as having cirrhosis by abdominal echographic findings, and 6 (21.4%) were diagnosed by liver histology. In 116 patients who developed HBeAg-negative hepatitis, 36 (31.0%) patients received histological examinations. In 56 patients who developed HBeAg-negative hepatitis flare, 26 (46.4%) patients received histological examinations. Of 8 patients who developed HCC, 7 were diagnosed by histological analysis.
Incidence Rates and Crude HRs by Univariate Analysis
The relationships between HBV-DNA levels and cumulative incidences of HBeAg-negative hepatitis, hepatitis flare, and cirrhosis are illustrated in Figure 3 . Serum HBV-DNA levels were positively associated with development of HBeAg-negative hepatitis, HBeAg-negative hepatitis flare, and cirrhosis (P for trend ,.001). Regarding HBeAg-negative hepatitis, compared with patients with serum HBV-DNA levels ,200 IU/mL, the crude HRs (Table 2 ).
Multivariate-Adjusted HRs
All of these factors analyzed in the univariate analysis were subjected to Cox regression analysis because they were associated with designated end points in univariate analysis. In terms of HBeAg-negative hepatitis, compared with patients with serum HBV-DNA levels ,200 IU/mL, the adjusted HR for those with serum HBV-DNA levels of 200-1999 IU/mL was 1.4 (95% CI, .7-2.8); 2000-19 999 IU/mL, 2.4 (95% CI, 1.3-4.4); 20 000-199 999 IU/mL, 3.6 (95% CI, 1.8-7.2); and .200 000 IU/mL, 5.3 (95% CI, 2.8-10.0). A similar dose-response relationship was also noted when evaluating the end points of HBeAg-negative hepatitis flare and cirrhosis, but not HCC (Table 3) .
Predicting HBeAg-Negative Hepatitis Within 3 Years and 6 Years by HBV-DNA Levels
Because every patient in this study had a different duration of follow-up, the HBV-DNA level was used to predict 3-year and 6-year risk of HBeAg-negative hepatitis. In both models, HBV-DNA levels could serve a predictor of HBeAg-negative hepatitis within 3 years (AUROC, 0. 
DISCUSSION
Spontaneous HBeAg seroconverters may enter either an inactive carrier state with low viremia, an HBeAg-negative hepatitis phase with reactivation of HBV replication, or seroreversion of HBeAg [2] . Patients in the HBeAg-negative hepatitis phase have been documented to be at risk for cirrhosis and HCC development [4] [5] [6] [7] . It is thus important to identify predictors of developing HBeAg-negative hepatitis. In line with previous studies, our results consistently showed that male sex, HBV genotype C infection, and older age at HBeAg seroconversion were independent risk factors of adverse outcomes after spontaneous HBeAg seroconversion [5, [7] [8] [9] [10] [11] . More importantly, we found that serum HBV-DNA level $2000 IU/mL at 1 year post HBeAg seroconversion increased the risk of HBeAg-negative hepatitis and hepatitis flare in a dose-response relationship, which corroborates our hypothesis.
From the literature review, several issues regarding HBeAgnegative hepatitis remain unclear. First, whether a higher serum HBV-DNA level is associated with an increased risk of hepatitis activity is controversial. Previous studies showed that 7%-55% of HBV carriers with persistently normal ALT levels had serum HBV-DNA levels $2000 IU/mL [23] [24] [25] [26] . To solve this controversy, a longitudinal cohort study with well-characterized baseline data and regular follow-up is required to clarify the causal relationship between serum HBV-DNA levels and hepatitis activity. Our data suggested that serum HBV-DNA levels $2000 IU/mL increase the risk of HBeAg-negative hepatitis over time. Second, the diagnosis of HBeAg-negative hepatitis is usually based on current consensus guidelines [16] [17] [18] . However, other liver diseases such as nonalcoholic steatohepatitis also cause mild hepatitis activity in patients with HBeAg-negative disease. To exclude this possibility, we included another end point of HBeAgnegative hepatitis flare, which is a more severe form of hepatitis and is less likely caused by etiologies other than hepatitis viruses. In other words, we not only investigated a soft end point, HBeAgnegative hepatitis, but also an additional solid end point, HBeAgnegative hepatitis flare, in this study. The consistent relationship between HBV-DNA levels and these 2 end points indicated that a higher viral load indeed drives hepatic necroinflammation. Our study has several unique points. First, we analyzed viral kinetics in a pilot study of 42 HBeAg seroconverters. We found that serum HBV-DNA levels began high but gradually declined and stabilized at 1 year post HBeAg seroconversion. Serum HBV-DNA levels at earlier time points were not associated with the emergence of HBeAg-negative hepatitis thereafter. This observation may partially explain why serum HBV-DNA levels within 6 months of HBeAg seroconversion were not an independent risk factor for adverse outcomes in a recent study [10] . Second, we excluded patients with serum ALT levels higher than twice the ULN and those who developed cirrhosis or HCC before the first year post HBeAg seroconversion. This is because these patients have already met the predefined end points and were recommended to receive antiviral therapy [16] [17] [18] . In other words, the remaining 390 spontaneous HBeAg seroconverters represented those who required a long-term followup as indicated by current management guidelines [16] [17] [18] .
This study had a few limitations. First, although histological examination remains the gold standard for confirming the diagnosis of cirrhosis, it is not practical to perform such an invasive procedure regularly and repeatedly to determine the stage of hepatic fibrosis in our daily clinical practice. In addition, other noninvasive methods, including transient elastography, have not been widely used in the management of chronic hepatitis B patients in the early 2000s. Therefore, cirrhosis was mostly diagnosed by abdominal echography supplemented with evidence of portal hypertension such as splenomegaly, gastroesophageal varices, thrombocytopenia, or ascites. However, clinical symptoms usually appear years after compensated cirrhosis occurs histologically, and imaging studies have a lower sensitivity for compensated cirrhosis. The possibility of underestimating the incidence of cirrhosis cannot be excluded, and thereby the analysis of factors associated with cirrhosis may be influenced. Second, not all of the patients in our cohort adhered well to the follow-up program. For example, when computing the cumulative incidence of HBeAg-negative hepatitis in 3 years and 6 years, only 348 (89.2%) and 280 (71.8%) patients were still followed up in this program. An underestimation of our end points is thus possible. Third, consistent with other cohorts of spontaneous HBeAg seroconverters [4, 5, 10] , the number of patients who developed HCC was relatively small (n 5 8). This limitation may explain why the association between serum HBV-DNA levels and HCC development could not be disclosed in other studies and ours. Larger cohort studies with a longer follow-up duration are mandatory to address this important issue. Finally, most of our patients did not receive antiviral therapy due to the constraint of previous reimbursement guidelines. Of 390 patients, 18 (4.6%) received antiviral therapy in the HBeAg-negative phase. The follow-up of treated patients was censored on the day of therapy initiation, which might affect our results. Nevertheless, the effect would be negligible due to its low percentage. Despite these limitations, this unique cohort of HBV carriers with well-documented timing of HBeAg seroconversion still provides practicing physicians broader and deeper understanding of risk factors related to HBeAg-negative hepatitis and hepatitis flare in spontaneous HBeAg seroconverters. In summary, HBeAg seroconversion may not always confer favorable clinical outcomes. In addition to male sex, HBV genotype C infection, and older age at HBeAg seroconversion, higher serum HBV-DNA level at 1 year post HBeAg seroconversion is positively associated with HBeAg-negative hepatitis and hepatitis flare in patients with HBeAg-negative disease.
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